Song et al. demonstrated the overexpression of H19 in bile duct ligation (BDL)-induced liver fibrosis with abnormal liver function parameters (Song et al., 2017), and identified a new downstream target gene of ZEB1, called EpCAM (Song et al., 2017), which promotes cholestatic liver fibrosis by interacting with the ZEB1 protein to prevent its binding to the EpCAM promoter and thus the inhibitory effect of ZEB1 (Song et al., 2017). This evidence concerns the gene ZEB1 and Hepatic fibrosis.